# US 6,730,330 B2 · Pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,330 B2
- Document ID: US6730330B2
- Status: Granted
- Kind: B2
- Application number: 09/827,158
- Filed: 2001-04-05
- Published: 2002-09-26
- Granted: 2004-05-04
- Earliest claimed: 2001-03-30
- Assignees: GW Pharma Limited
- Inventors: Brian A. Whittle; Geoffrey W. Guy
- Web page: https://patentgrep.com/patent/US6730330B2

## CPC

- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/122: {Foams; Dry foams (edible foams A61K9/0056)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to pharmaceutical formulations for use in the administration of medicaments, in particular lipophilic medicaments, via mucosal surfaces.

## Claims

### Claim 1

A pharmaceutical formulation for use in administration of cannabinoids via a mucosal surface, the formulation comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) and a matrix comprising at least one agent which is both a self-emulsifier and a cannabinoid solubilizer, said agent when hydrated forming an emulsion containing said THC and CBD which is capable of adhering reversibly to a mucosal surface and allowing controlled release of the THC and CBD.

### Claim 2 (depends on 1)

A pharmaceutical formulation according to claim 1, wherein said agent which is both a self emulsifier and a cannabinoid solubilizer is selected from the group consisting of glycerol monooleate, glycerol monostearate, medium chain triglycerides, polyethoxylated caster oil, polyoxyethylene alkyl ethers, polyoxyethylene ethers, polyoxyetyhlene fatty acid eaters, polyoxyothylene stoarates and sorbitan esters.

### Claim 3 (depends on 2)

A pharmaceutical formulation according to claim 2, wherein said agent which is both a self-emulsifier and a cannabinoid solubilizer is polyoxyethylene caster oil.

### Claim 4 (depends on 2)

A pharmaceutical formulation according to claim 2, wherein said agent which is both a self-emulsifier and a cannabinoid solubilizer is a cremophore.

### Claim 5 (depends on 2)

A pharmaceutical formulation according to claim 2, which includes ethanol, wherein said agent which is both a self-emulsifier and a cannabinoid solubilizer is a cremophore.

### Claim 6 (depends on 1)

A pharmaceutical formulation according to claim 1, wherein the ratio of THC to CBD is selected from the group consisting of: a ratio of THC:CBD of 2:1, a ratio of THC:CBD of 1:1 and a ratio of THC:CBD of 1:2.

### Claim 7 (depends on 1)

A pharmaceutical formulation according to claim 1, wherein the matrix further comprises one or more viscolising agents.

### Claim 8 (depends on 7)

A pharmaceutical formulation according to claim 7, wherein the matrix comprises at least on viscolising agent that when hydrated forms a gel having positive surface electrical charge and at least one viscolising agent that when hydrated forms a gel having negative surface electrical charge.

### Claim 9 (depends on 7)

A pharmaceutical formulation according to claim 7, wherein at least one of the viscolising agents is solubilized by the action of an enzyme present in saliva.

### Claim 10 (depends on 7)

A pharmaceutical formulation according to claim 7, wherein the viscolising agent is a carbohydrate.

### Claim 11 (depends on 7)

A pharmaceutical formulation according to claim 7, wherein the viscolising agent is starch.

### Claim 12 (depends on 1)

A pharmaceutical formulation according to claim 1 which is in the form of a gel, a compressed tablet, a liquid or a capsule.

### Claim 13 (depends on 1)

A pharmaceutical formulation according to claim 1 which is in the form of a gel for administration of one or more cannabinoids via the sublingual and/or buccal mucosae, wherein on contact with saliva the gel forms an emulsion containing said at least one cannabis extract that adheres reversibly to the sublingual and/or buccal mucosae.

### Claim 14 (depends on 1)

A pharmaceutical formulation according to claim 1, which includes at least one cannabis extract.

### Claim 15

A pharmaceutical formulation for use in administration of at least one cannabis extract “containing the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD)” via a mucosal surface, the formulation comprising said at least one cannabis extract and a matrix comprising at least one agent which is both a self-emulsifier and a cannabinoid solubilizer, said agent when hydrated forming an emulsion containing said at least one cannabis extract “containing the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD)” which is capable of adhering reversibly to a mucosal surface and allowing controlled release of the cannabinoids from said extract “containing the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD)”.

### Claim 16 (depends on 15)

A pharmaceutical formulation according to claim 15 wherein said agent which is both a self-emulsifier and a cannabinoid solubilizer is selected from the group consisting of glycerol monooleate, glycerol monostearate, medium chain triglycerides, polyethoxylated caster oil, polyoxyethylene alkyl ethers, polyoxyethylene ethers, polyoxyethylene fatty acid esters, polyoxyethylene stearates and sorbitan esters.
